Publication | Open Access
Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin <i>vs</i> placebo or empagliflozin in patients with type 2 diabetes and heart failure
63
Citations
26
References
2020
Year
The reduction in NT-proBNP with licogliflozin suggests a potential benefit of SGLT1 and 2 inhibition in patients with T2DM and heart failure.
| Year | Citations | |
|---|---|---|
Page 1
Page 1